LRP4 and myasthenia gravis: Additionally, more patients were classified as MGFA IVb-V in the AChR+Titin-MG group than in either the AChR-MG and AChR+LRP4-MG groups (48.2 vs. 33.2, and 24.1%, P = 0.02).